预测N0期非小细胞肺癌淋巴血管侵犯:基于双能CT影像与临床特征列线图
回顾性纳入两家医院135例术前接受双能CT的N0期非小细胞肺癌患者,开发队列107例、验证队列28例,以淋巴细胞计数、动脉期碘浓度、静脉期标准化碘浓度及分形维数构建列线图预测淋巴血管侵犯,开发队列AUC 0.819(95%CI 72.6-90.4),外部验证AUC 0.844(95%CI 68.2-95.8),校准曲线显示预测概率与实际阳性率高度一致。
要点
- 静脉期标准化碘浓度(NICv)OR 587.12、P=0.009,为列线图中权重最大的独立预测因子。
- 动脉期碘浓度(ICa)OR 1.25、P=0.021,淋巴细胞计数(LYMPH)OR 3.71、P=0.014,分形维数(FD)OR 0.01、P=0.033。
- 列线图外部验证AUC 0.844(95%CI 68.2-95.8),校准曲线示预测概率与实际阳性率高度一致。
核心结论
- 联合临床特征与双能CT影像表现(LYMPH、ICa、NICv、FD)构建的列线图有助于预测N0期非小细胞肺癌的淋巴血管侵犯,开发队列与验证队列AUC分别为0.819(95%CI 72.6-90.4)和0.844(95%CI 68.2-95.8),外部验证校准曲线显示预测概率与实际阳性率高度一致。
研究设计与样本
- 回顾性研究,从两家医院招募135例N0期非小细胞肺癌患者,术前均行双能CT,分为开发队列107例和验证队列28例,收集临床特征(基线特征、生化标志物、血清肿瘤标志物、免疫组化标志物)、双能CT参数(碘浓度IC、有效原子序数Eff-Z、标准化碘浓度NIC、碘强化IE、NIC比值NICr)及分形维数FD,构建列线图并外部验证。
诊断标准与关键数值
- 多因素分析显示淋巴细胞计数(LYMPH,OR 3.71,P=0.014)、动脉期碘浓度(ICa,OR 1.25,P=0.021)、静脉期标准化碘浓度(NICv,OR 587.12,P=0.009)及分形维数(FD,OR 0.01,P=0.033)为预测淋巴血管侵犯的独立显著因素并用于构建列线图;列线图开发队列AUC 0.819(95%CI 72.6-90.4),验证队列AUC 0.844(95%CI 68.2-95.8);外部验证校准曲线显示预测概率与实际阳性率高度一致。
临床应用与阅片要点
- 作者认为联合临床与双能CT影像表现可借助LYMPH、ICa、NICv和FD等显著指标构建列线图协助预测N0期非小细胞肺癌的淋巴血管侵犯。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To construct a nomogram for predicting lymphovascular invasion (LVI) in N0 stage non-small cell lung cancer (NSCLC) using dual-energy computed tomography (DECT) findings combined with clinical findings.
METHODS: We retrospectively recruited 135 patients with N0 stage NSCLC from two hospitals underwent DECT before surgery and were divided into development cohort (n = 107) and validation cohort (n = 28). The clinical findings (baseline characteristics, biochemical markers, serum tumor markers and Immunohistochemical markers), DECT-derived parameters (iodine concentration [IC], effective atomic number [Eff-Z] and normalized iodine concentration [NIC], iodine enhancement [IE] and NIC ratio [NICr]) and Fractal dimension (FD) were collected and measured. A nomogram was constructed using significant findings to predict LVI in N0 stage NSCLC and was externally validated.
RESULTS: Multivariable analysis revealed that lymphocyte count (LYMPH, odds ratio [OR]: 3.71, P=0.014), IC in arterial phase (ICa, OR: 1.25, P=0.021), NIC in venous phase (NICv, OR: 587.12, P=0.009) and FD (OR: 0.01, P=0.033) were independent significant factors for predicting LVI in N0 stage NSCLC, and were used to construct a nomogram. The nomogram exhibited robust predictive capabilities in both the development and validation cohort, with AUCs of 0.819 (95 % CI: 72.6-90.4) and 0.844 (95 % CI: 68.2-95.8), respectively. The calibration plots showed excellent agreement between the predicted probabilities and the actual rates of positive LVI, on external validation.
CONCLUSIONS: Combination of clinical and DECT imaging findings could aid in predicting LVI in N0 stage NSCLC using significant findings of LYMPH, ICa, NICv and FD.
引用
- Deng L, Yang J, Zhang M, et al. Predicting lymphovascular invasion in N0 stage non-small cell lung cancer: A nomogram based on Dual-energy CT imaging and clinical findings. Eur J Radiol. 2024. PMID: 39116778. doi:10.1016/j.ejrad.2024.111650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。